Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.67 |
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.59 |
| ▸ | HRH1 | P35367 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723732 | 0.87 | HRH3 (0.88) | HRH3HRH4HRH1 | |
| SCHEMBL9228886 | 0.85 | HRH3 (0.85) | HRH3HRH4HRH1 | |
| SCHEMBL12138199 | 0.85 | HRH3 (0.85) | HRH3HRH4HRH1 | |
| SCHEMBL6909231 | 0.85 | HRH3 (0.85) | HRH3HRH4HRH1 | |
| SCHEMBL19182601 | 0.85 | HRH3 (0.85) | HRH3HRH4HRH1 | |
| SCHEMBL1031431 | 0.81 | — | — | |
| SCHEMBL8963957 | 0.75 | HRH3 (0.80) | HRH3HRH4HRH1 | |
| SCHEMBL8963886 | 0.73 | HRH3 (0.75) | HRH3HRH4HRH1 | |
| SCHEMBL16135286 | 0.72 | HIF1A (0.49) | — | |
| SCHEMBL3682342 | 0.71 | TRPV1 (0.73) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130302247-A1 | SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-11-14 | — | — | US | disclosed |
| US-20090036410-A1 | Structured Phospholipids | BTG INTERNATIONAL LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-1885377-A2 | STRUCTURED PHOSPHOLIPIDS FOR TREATING AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | BTG INTERNATIONAL LIMITED (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006056783-A2 | STRUCTURED PHOSPHOLIPIDS FOR TREATING AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | BTG INTERNATIONAL LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036410-A1 | Structured Phospholipids | SGMS1, SGMS2, SMPD1 | HRH3 2314/4885HRH4 2426/4885HRH1 2078/4885 |
| US-20130302247-A1 | SYNTHESIS OF FLUOROARACHIDONIC ACID AND METHODS OF USE THEREOF | ALOX15B, ALOX15, ALOX5 | HRH3 775/4885HRH4 822/4885HRH1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.